liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop
Copenhagen Univ Hosp, Denmark; Natl Univ Singapore, Singapore.
Copenhagen Univ Hosp, Denmark; Natl Univ Singapore, Singapore.
Oslo Univ Hosp, Norway.
Scottish Natl Blood Transfus Serv, Scotland.
Show others and affiliations
2019 (English)In: Vox Sanguinis, ISSN 0042-9007, E-ISSN 1423-0410, Vol. 114, no 4, p. 386-393Article in journal (Refereed) Published
Abstract [en]

Background and Objectives Fetal RHD genotyping of cell-free fetal DNA from RhD-negative pregnant women can be used to guide targeted antenatal and postnatal anti-D prophylaxis for the prevention of RhD immunization. To assure the quality of clinical testing, we conducted an external quality assessment workshop with the participation of 28 laboratories. Materials and Methods Aliquots of pooled maternal plasma were sent to each laboratory. One sample was positive, and the second sample was negative for fetal RHD, verified by pre-workshop testing using quantitative real-time PCR (qPCR) analysis of RHD exons 4, 5, 7 and 10. Plasma samples were shipped at room temperature. A reporting scheme was supplied for data collection, including questions regarding the methodological setup, results and clinical recommendations. Different methodological approaches were used, all employing qPCR with a total of eight different combinations of RHD exon targets. The samples were tested blindly. Results Fetal RHD genotyping was performed with no false-negative and no false-positive results. One inconclusive result was reported for the RHD-positive sample, and four inconclusive results were reported for the RHD-negative sample. All clinical conclusions were satisfactory. Conclusion This external quality assessment workshop demonstrates that despite the different approaches taken to perform the clinical assays, fetal RHD genotyping is a reliable laboratory assay to guide targeted use of Rh prophylaxis in a clinical setting.

Place, publisher, year, edition, pages
WILEY , 2019. Vol. 114, no 4, p. 386-393
Keywords [en]
fetal RHD genotyping; cell-free fetal DNA; external quality assessment; Rh prophylaxis
National Category
Hematology
Identifiers
URN: urn:nbn:se:liu:diva-158851DOI: 10.1111/vox.12768ISI: 000470935800012PubMedID: 30834546OAI: oai:DiVA.org:liu-158851DiVA, id: diva2:1337645
Available from: 2019-07-16 Created: 2019-07-16 Last updated: 2019-07-16

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Holmertz, CamillaNyström, Sofia
By organisation
Department of Clinical and Experimental MedicineFaculty of Medicine and Health SciencesDepartment of Clinical Immunology and Transfusion MedicineDivision of Hematopoiesis and Developmental Biology
In the same journal
Vox Sanguinis
Hematology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 24 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf